SCHEMBL3498977

SCHEMBL3498977

CCN1CCCC2(CCCN(C(=O)OC(C)(C)C)C2)C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.45
ACACB O00763 2/20 0.41
ACACA Q13085 2/20 0.41
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAPT P10636 2/20 0.38
MMP2 P08253 1/20 0.38
MMP13 P45452 1/20 0.38
MMP14 P50281 1/20 0.38
ADAM17 P78536 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.37
NR1H2 P55055 1/20 0.37
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CTSK P43235 1/20 0.36
NAMPT P43490 3/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3499124 0.96 USP30 (0.47) USP30ACACBACACAGRIN2BGRIN2C
SCHEMBL3497285 0.86 USP30 (0.45) USP30ACACBACACAGRIN2BGRIN2C
SCHEMBL17082036 0.82 USP30 (0.49) USP30GRIN2BGRIN2CMEN1KMT2A
SCHEMBL3497947 0.82 USP30 (0.49) USP30GRIN2BGRIN2CMEN1KMT2A
SCHEMBL3494726 0.81 ACACB (0.58) USP30ACACBACACAMEN1KMT2A
SCHEMBL3498100 0.80 USP30 (0.39) USP30GRIN2BGRIN2CMEN1KMT2A
SCHEMBL26378530 0.79 USP30 (0.43) USP30ACACBGRIN2BGRIN2CMEN1
SCHEMBL3497329 0.79 USP30 (0.47) USP30ACACBACACAGRIN2BGRIN2C
SCHEMBL5426355 0.78 USP30 (0.45) USP30ALDH1A1HPGDNAMPTHDAC1
SCHEMBL31645803 0.77 USP30 (0.42) USP30ACACBGRIN2BGRIN2CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
US-20100160255-A1 SPIRO-CYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-06-24 US disclosed
EP-1911753-A1 SPIRO-CYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2008-04-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160255-A1 SPIRO-CYCLIC COMPOUND ACACA, CPT1B, PC USP30 3125/4885ACACB 6/4885ACACA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.